Search Results - "Nolin, Thomas D"

Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment by Vijayan, Anitha, MD, Faubel, Sarah, MD, Askenazi, David J., MD, MSPH, Cerda, Jorge, MD, Fissell, William H., MD, Heung, Michael, MD, Humphreys, Benjamin D., MD, PhD, Koyner, Jay L., MD, Liu, Kathleen D., MD, PhD, Mour, Girish, MBBS, MD, Nolin, Thomas D., PharmD, PhD, Bihorac, Azra, MD

“…Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences…”
Get full text

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP by Tan, Ming‐Liang, Yoshida, Kenta, Zhao, Ping, Zhang, Lei, Nolin, Thomas D., Piquette‐Miller, Micheline, Galetin, Aleksandra, Huang, Shiew‐Mei

“…Our recent studies have shown that chronic kidney disease (CKD) affects the pharmacokinetics (PKs) of cytochrome P450 (CYP)2D6‐metabolized drugs, whereas…”
Get full text

Development and validation of a simple UHPLC–MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine by Ocque, Andrew J., Stubbs, Jason R., Nolin, Thomas D.

“…•An UHPLC–MS/MS method for measurement of TMAO, choline and betaine in human plasma and urine.•The method is validated with high accuracy and precision.•The…”
Get full text

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates by Tan, Ming‐Liang, Zhao, Ping, Zhang, Lei, Ho, Yunn‐Fang, Varma, Manthena V.S., Neuhoff, Sibylle, Nolin, Thomas D., Galetin, Aleksandra, Huang, Shiew‐Mei

“…Chronic kidney disease (CKD) differentially affects the pharmacokinetics (PK) of nonrenally cleared drugs via certain pathways (e.g., cytochrome P450…”
Get full text

Simultaneous determination of total homocysteine, cysteine, cysteinylglycine, and glutathione in human plasma by high-performance liquid chromatography: Application to studies of oxidative stress by Nolin, Thomas D., McMenamin, M. Elizabeth, Himmelfarb, Jonathan

“…A sensitive, reproducible, and robust high-performance liquid chromatography (HPLC) method has been validated for simultaneously determining total…”
Get full text

Bridging Translation by Improving Preclinical Study Design in AKI by de Caestecker, Mark, Humphreys, Ben D, Liu, Kathleen D, Fissell, William H, Cerda, Jorge, Nolin, Thomas D, Askenazi, David, Mour, Girish, Harrell, Jr, Frank E, Pullen, Nick, Okusa, Mark D, Faubel, Sarah

“…Despite extensive research, no therapeutic interventions have been shown to prevent AKI, accelerate recovery of AKI, or reduce progression of AKI to CKD in…”
Get full text

Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio–Related Hemorrhage in Warfarin Users: A Prospective Cohort Study by Limdi, Nita A., PharmD, PhD, Nolin, Thomas D., PharmD, PhD, Booth, Sarah L., PhD, Centi, Amanda, MS, Marques, Marisa B., MD, Crowley, Michael R., PhD, Allon, Michael, MD, Beasley, T. Mark, PhD

“…Background Anticoagulation management is difficult in chronic kidney disease, with frequent supratherapeutic international normalized ratios (INRs ≥ 4)…”
Get full text

Hemoperfusion for the Treatment of Poisoning: Technology, Determinants of Poison Clearance, and Application in Clinical Practice by Ghannoum, Marc, Bouchard, Josée, Nolin, Thomas D., Ouellet, Georges, Roberts, Darren M.

“…Hemoperfusion is an extracorporeal treatment based on adsorption, historically reserved for the treatment of acute poisonings. Its use was popularized in the…”
Get full text

Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding: A Single Center Experience by Singh, Tripti, Maw, Thin Thin, Henry, Brian L, Pastor-Soler, Núria M, Unruh, Mark L, Hallows, Kenneth R, Nolin, Thomas D

“…Dabigatran is an oral direct thrombin inhibitor that is Food and Drug Administration-approved for prevention of stroke in patients with atrial fibrillation. No…”
Get full text

Extracorporeal Treatment for Barbiturate Poisoning: Recommendations From the EXTRIP Workgroup by Mactier, Robert, MD, Laliberté, Martin, MD, MSc, Mardini, Joelle, MD, Ghannoum, Marc, MD, Lavergne, Valery, MD, MSc, Gosselin, Sophie, MD, Hoffman, Robert S., MD, Nolin, Thomas D., PharmD, PhD

“…The EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup conducted a systematic review of barbiturate poisoning using a standardized evidence-based…”
Get full text

Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimating Equations by Stevens, Lesley A., MD, MS, Nolin, Thomas D., PharmD, PhD, Richardson, Michelle M., PharmD, Feldman, Harold I., MD, MSCE, Lewis, Julia B., MD, Rodby, Roger, MD, Townsend, Raymond, MD, Okparavero, Aghogho, MBBS, MPH, Zhang, Yaping (Lucy), MS, Schmid, Christopher H., PhD, Levey, Andrew S., MD

“…Background Kidney disease alters the pharmacokinetic disposition of many medications, requiring dosage adjustment to maintain therapeutic serum concentrations…”
Get full text

Implications of Kidney Disease on Metabolic Reduction by Alshogran, Osama Y, Nolin, Thomas D

“…Chronic kidney disease (CKD) modulates the nonrenal clearance of drugs by altering their metabolism and/or transport. While the effects of CKD on pathways of…”
Get more information

Effect of CKD and Dialysis Modality on Exposure to Drugs Cleared by Nonrenal Mechanisms by Thomson, Benjamin K.A., MSc, MD, Nolin, Thomas D., PharmD, PhD, Velenosi, Thomas J., BMSc, Feere, David A., BMSc, MSc, Knauer, Michael J., BMSc, PhD, Asher, Linda J., RN, House, Andrew A., MSc, MD, Urquhart, Bradley L., PhD

“…Background Patients with kidney disease frequently experience adverse effects from medication exposure, even when drugs are cleared by nonrenal pathways…”
Get full text

Current Understanding of Drug Disposition in Kidney Disease by Naud, Judith, Nolin, Thomas D., Leblond, Francois A., Pichette, Vincent

“…Patients with chronic kidney disease (CKD) represent 13% of the American population. CKD has been shown to significantly alter drug disposition of nonrenally…”
Get full text

Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup by Bouchard, Josée, Shepherd, Greene, Hoffman, Robert S, Gosselin, Sophie, Roberts, Darren M, Li, Yi, Nolin, Thomas D, Lavergne, Valéry, Ghannoum, Marc

“…β-adrenergic antagonists (BAAs) are used to treat cardiovascular disease such as ischemic heart disease, congestive heart failure, dysrhythmias, and…”
Get full text

Simultaneous analysis of multiple aminothiols in human plasma by high performance liquid chromatography with fluorescence detection by McMenamin, M. Elizabeth, Himmelfarb, Jonathan, Nolin, Thomas D.

“…Aminothiols serve numerous vital functions in biochemistry, including detoxification and regulation of cellular metabolism, enzymatic activity, and protein…”
Get full text

Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup by Anseeuw, Kurt, MD, MSc, Mowry, James B., PharmD, Burdmann, Emmanuel A., MD, PhD, Ghannoum, Marc, MDCM, Hoffman, Robert S., MD, Gosselin, Sophie, MD, Lavergne, Valery, MD, MSc, Nolin, Thomas D., PharmD, PhD

“…The Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup conducted a systematic literature review using a standardized process to develop evidence-based…”
Get full text

Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children by Clark, Robert S B, Empey, Philip E, Bayır, Hülya, Rosario, Bedda L, Poloyac, Samuel M, Kochanek, Patrick M, Nolin, Thomas D, Au, Alicia K, Horvat, Christopher M, Wisniewski, Stephen R, Bell, Michael J

“…There are no therapies shown to improve outcome after severe traumatic brain injury (TBI) in humans, a leading cause of morbidity and mortality. We sought to…”
Get full text

Metformin for sepsis-associated AKI: a protocol for the Randomized Clinical Trial of the Safety and FeasibiLity of Metformin as a Treatment for sepsis-associated AKI (LiMiT AKI) by Saraiva, Ivan E, Hamahata, Natsumi, Huang, David T, Kane-Gill, Sandra L, Rivosecchi, Ryan M, Shiva, Sruti, Nolin, Thomas D, Chen, Xinlei, Minturn, John, Chang, Chung-Chou H, Li, Xiaotong, Kellum, John, Gómez, Hernando

“…IntroductionAcute kidney injury (AKI) is a common complication of sepsis associated with increased risk of death. Preclinical data and observational human…”
Get full text

Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest by Goldstein, Ellie J. C., Owens, Robert C., Nolin, Thomas D.

“…Until recently, cardiac toxicity manifesting in the form of arrhythmias related to QT interval prolongation was uncommonly appreciated within the antimicrobial…”
Get full text